Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.
Senseonics Holdings, Inc. reports developments tied to its long-term, implantable continuous glucose monitoring systems for people with diabetes. The company designs, develops, manufactures and commercializes the Eversense CGM platform, including Eversense 365 and Eversense E3, which use an under-the-skin sensor, a wearable smart transmitter and a mobile app for glucose data.
Recurring news for SENS covers financial results, U.S. and European commercialization, CE Mark and product-launch activity, automated insulin delivery integrations, and pipeline work on Gemini and Freedom systems. Company updates also include capital actions such as common stock and pre-funded warrant offerings, loan-facility amendments, and funding for Eversense 365 commercialization and product development.
Senseonics Holdings, Inc. (NYSE American: SENS) reported a revenue of $3.7 million for Q2 2022, up from $3.3 million in Q2 2021. The U.S. revenue increased to $1.2 million from $1.0 million year-over-year. Gross profit improved to $0.8 million, up from $0.4 million. Notably, the company recorded a net income of $104.2 million, attributed to adjustments in embedded derivatives. Senseonics also reaffirmed its full-year revenue guidance of $14.0 million to $18.0 million. Recent highlights included CE mark approval for the E3 system and improved patient access through coverage decisions.
Senseonics Holdings, Inc. (AMEX: SENS) announced that Anthem is providing coverage for its Eversense E3 Continuous Glucose Monitoring (CGM) System, adding over 45 million covered lives. This expands the total coverage for Eversense to approximately 250 million lives in the U.S. The Eversense CGM offers a six-month sensor life, accurate glucose data, and remote monitoring capabilities for diabetes management. The decision follows similar coverage expansions by other major insurers, enhancing the accessibility of this advanced monitoring technology.
Senseonics Holdings, Inc. (NYSE American: SENS) announced plans to release its Q2 2022 financial results on August 9, 2022, after market close. Management will review the performance during a conference call at 4:30 p.m. (ET), which will be available via a webcast on the company's website. Senseonics specializes in long-term implantable continuous glucose monitoring (CGM)/b) systems, including Eversense®, Eversense® XL, and Eversense® E3, providing automatic glucose data updates every five minutes to users' mobile apps.
Senseonics Holdings, Inc. (NYSE American: SENS) announced equity grants to 17 new non-executive employees under its 2019 Inducement Plan. Each employee received non-qualified stock options to purchase 199,000 shares at an exercise price of $1.02 per share, corresponding to the closing price on July 1, 2022. The options will vest over four years, contingent on continued employment. Senseonics aims to expand its Eversense Continuous Glucose Monitoring (CGM) System for diabetes management globally.
Senseonics Holdings, Inc. has received CE Mark approval for the Eversense® E3 CGM System, allowing commercialization in select European markets. The E3 system is the longest-lasting continuous glucose monitoring device, with a wear duration of up to 6 months and superior accuracy. Ascensia Diabetes Care, Senseonics’ commercial partner, will launch the product in Germany, Italy, Spain, and other EU countries starting Q3 2022. The E3 system enhances operational efficiency and supports non-adjunctive use, improving treatment decisions without confirmatory fingerstick tests.
Senseonics Holdings, Inc. (AMEX: SENS) announced its participation in the Jefferies Healthcare Conference in New York, scheduled for June 9, 2022, at 1:30pm ET. The presentation will be accessible via a live and recorded webcast on the company's website. Senseonics specializes in developing long-term, implantable continuous glucose monitoring systems, including Eversense® devices, designed to aid diabetes management. The company aims to transform lives by providing innovative glucose monitoring solutions.
Senseonics Holdings, Inc. (AMEX: SENS) has announced its participation in the hybrid H.C. Wainwright Global Investment Conference on May 24, 2022. Management will engage in virtual one-on-one meetings, with a webcast presentation starting at 7:00 AM ET. The company specializes in implantable continuous glucose monitoring (CGM) systems, aimed at enhancing diabetes management. Their products include Eversense®, Eversense® XL, and Eversense® E3, which transmit glucose data to smartphones every five minutes.
Senseonics Holdings, Inc. (SENS) reported Q1 2022 financial results, showcasing total revenue of $2.5 million, a decrease from $2.8 million in Q1 2021. U.S. revenue rose to $0.8 million, while international revenue dropped to $1.7 million. The net income for Q1 2022 was reported at $86.7 million, significantly higher than the net loss of $249.5 million in Q1 2021, primarily due to adjustments in embedded derivatives. The gross profit remained stable at $0.5 million, though expenses increased due to R&D and operational costs. The company anticipates full-year 2022 net revenue between $14 million and $18 million.
Senseonics Holdings, Inc. (SENS) plans to release its first quarter 2022 financial results after market close on May 10, 2022. A conference call to discuss its performance will start at 4:30 p.m. ET on the same day, accessible via a dedicated webcast on their website. Senseonics focuses on developing long-term, implantable continuous glucose monitoring (CGM) systems for diabetes management, with products like Eversense® and Eversense® E3, which automatically send glucose data to smartphones every 5 minutes.
Senseonics Holdings, Inc. (AMEX: SENS) has announced the successful implantation of the first patient with the Eversense® E3 Continuous Glucose Monitoring (CGM) System in the U.S. This system, which received FDA approval in February, offers a 6-month sensor life, making it the longest-lasting CGM available. It features exceptional accuracy with a mean absolute relative difference (MARD) of 8.5%, reduced calibration frequency, and discreet on-body alerts. The Eversense E3 marks a significant advancement in diabetes care, enabling patients to manage their condition with improved confidence and convenience.